Skip to content

A randomized, controlled trial for the efficacy and safety of acupuncture for the chronic atrophic gastritis based on the Doctor-patient Co-operated Evidence-based Medical Record

A randomized, controlled trial for the efficacy and safety of acupuncture for the chronic atrophic gastritis based on the Doctor-patient Co-operated Evidence-based Medical Record

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019810
Enrollment
Unknown
Registered
2018-11-30
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the chronic atrophic gastritis

Interventions

Group 2:Acupuncture combined with Guideline

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with the chronic atrophic gastritis (confirmed by gastroscopy and pathological diagnosis in the Grade ? hospitals within three months); 2. With a TCM syndrome differentiation of spleen qi stagnation, spleen and stomach damp heat, liver and stomach stagnation fever, etc; 3. Aged between 30 and 70 years old; 4. Willing and guarantee to sign the informed consent and cooperate in accordance with program requirements.

Exclusion criteria

Exclusion criteria: 1. Patients who are eligible for chronic atrophic gastritis or precancerous lesions, but with peptic ulcers or malignant tumors; 2. Patients with diabetes; 3. Patients with uncontrolled grade III hypertension (systolic blood pressure =180 mmHg and / or diastolic blood pressure =110 mmHg); 4. Patients with severe arrhythmia (such as rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc.); 5. Patients with severe heart, liver, kidney and hematopoietic system disease, as well as mental disorders and malignant tumors; 6. Patients with active peptic ulcer and other bleeding disorders; 7. Pregnancy or preparation for pregnant women, lactating women; 8. Allergic constitution; 9. Those who have participated in or are participating in other clinical trials within the past three months.

Design outcomes

Primary

MeasureTime frame
symptom index;rate;

Secondary

MeasureTime frame
frequency;total doses;rate;Adverse events;

Countries

China

Contacts

Public ContactGuihua Tian

Dongzhimen Hospital, Beijing University of Chinese Medicine

rosetgh@163.com+86 13717697488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026